Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversibly binding P2Y12 platelet inhibitor.
## Primary Indications
* In combination with aspirin, ticagrelor is indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Adult Dosing
* **ACS:**
* An initial loading dose of 180 mg orally once.
* Followed by 90 mg orally twice daily for up to 12 months.
* **Post-MI (at least 1 year after ACS):**
* In patients who have had an MI at least 1 year prior and are treated with aspirin, ticagrelor 60 mg orally twice daily is indicated to reduce the rate of thrombotic cardiovascular events. This indication is for patients with a high risk of a further thrombotic cardiovascular event.
## Pediatric Dosing
* Ticagrelor is not recommended for use in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is required for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment due to limited data.
* **Renal Impairment:** No dose adjustment required for mild to moderate renal impairment. In severe renal impairment, caution is advised.
## Contraindications
* Active bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Most Common:** Bleeding (dyspnea, bruising, epistaxis, gastrointestinal bleeding), bradycardia, ventricular pauses, syncope, dizziness, headache.
* **Serious:** Life-threatening bleeding, severe dyspnea, atrial fibrillation.
## Key Drug Interactions
* **CYP3A4 Substrates/Inhibitors:** Ticagrelor is a substrate of CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase ticagrelor plasma concentrations and risk of bleeding. Co-administration with strong CYP3A4 inducers (e.g., rifampin) can decrease ticagrelor plasma concentrations and efficacy.
* **Aspirin:** Additive antiplatelet effects leading to increased bleeding risk.
* **Anticoagulants (e.g., Warfarin, Heparin):** Increased risk of bleeding.
* **UGT1A1 Substrates:** Ticagrelor can inhibit UGT1A1, potentially increasing the exposure of co-administered UGT1A1 substrates.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for signs of dyspnea.
* ECG monitoring for bradycardia or pauses, particularly in patients with pre-existing risk factors.
## Clinical Pearls
* Ticagrelor is administered as two 90 mg tablets or one 180 mg tablet for the initial loading dose in ACS.
* Dose is 90 mg BID for ACS patients for up to 12 months.
* Dose is 60 mg BID for post-MI patients with high risk of recurrent events (at least 1 year post-ACS).
* Dose interruption for procedures should be carefully considered in light of the patient's thrombotic risk.
* Dose is administered regardless of food intake.
* Concurrent use of aspirin should be for the duration of ticagrelor therapy unless specifically indicated otherwise.
---
*This information is intended for educational purposes and does not substitute for professional medical advice. Always consult the current prescribing information and a qualified healthcare provider for any medical decisions.*
